The formula is elegant in its simplicity and far-reaching in its consequences. Medicare Part B reimburses most physician-administered drugs at the average sales price plus six percent, a rate set by CMS and adjusted quarterly based on manufacturer-reported sales data. The six percent margin is intended to cover the costs physicians incur in purchasing, storing, and administering injectable and infused therapies. In practice, it has become something far more consequential: a financial signal that shapes prescribing behavior, influences manufacturer pricing strategy, and sustains an entire segment of the healthcare economy.
ASP itself is a volume-weighted average of a drug’s actual sales prices to all purchasers, net of discounts, chargebacks, prompt-pay adjustments, and rebates — including those paid under the Medicaid Drug Rebate Program. It is, in theory, the closest publicly available approximation of what a manufacturer actually receives for a drug after all concessions clear. The two-quarter lag in reporting means today’s reimbursement rate reflects prices from six months ago, a delay that creates arbitrage opportunities when market prices move faster than the benchmark updates.
The buy-and-bill model that ASP-based reimbursement supports is unusual in medicine. In most of healthcare, providers are paid for services and drugs are reimbursed separately through pharmacy benefits. In the physician-administered space, the provider buys the drug at wholesale, administers it, and bills Medicare for reimbursement at ASP plus six percent. If the physician’s acquisition cost is below ASP — which it often is, because ASP is an average and sophisticated purchasers can negotiate below-average prices — the difference becomes margin. The six percent markup then applies to a figure that already exceeds the provider’s cost, amplifying the spread.
This arithmetic produces a well-documented incentive: all else being equal, a higher-priced drug generates a larger absolute margin under ASP plus six percent. Six percent of a $10,000 drug is $600. Six percent of a $1,000 drug is $60. The percentage is the same. The dollars are not. For oncology practices, where physician-administered drugs constitute a substantial revenue stream, the financial incentive to choose higher-cost therapies — when clinical evidence supports comparable efficacy — is structural, not speculative.
The oncology community has pushed back against this characterization, arguing that clinical judgment drives prescribing and that margins on drugs merely offset the unprofitability of other services. Both claims have merit. But the American Journal of Managed Care has published analyses documenting the behavioral effects of ASP-based reimbursement, and the pattern is difficult to dismiss entirely. When biosimilars enter the market at lower prices, adoption has sometimes been slower than therapeutic equivalence alone would predict. The financial dynamics of ASP plus six percent are one plausible explanation among several.
The sequestration adjustment complicates matters further. Since 2013, Medicare reimbursement for Part B drugs has been subject to a two percent reduction under budget sequestration, effectively reducing the margin from six percent to approximately 4.3 percent after the cut applies. For lower-cost drugs, this compressed margin can fall below the actual cost of acquisition, storage, and administration, making some therapies financially unviable to stock. The sequestration effect is regressive in the sense that it disproportionately pressures providers who use lower-cost products — precisely the opposite of what cost-containment policy would intend.
Biosimilars occupy an interesting position within this framework. CMS reimburses certain biosimilar drugs at the reference brand’s ASP plus eight percent, a temporary payment increase created to incentivize biosimilar adoption. The rationale is transparent: without a margin premium, the ASP-plus-six arithmetic naturally favors higher-priced reference biologics. The biosimilar premium attempts to counteract this by making the generic alternative more financially attractive to prescribers. Whether a two-percentage-point differential is sufficient to overcome institutional switching costs, clinical inertia, and the rebate structures that reference biologic manufacturers offer to maintain market share is an empirical question with mixed evidence.
The two-quarter lag in ASP reporting deserves more attention than it typically receives. A manufacturer that launches a drug at a high price and subsequently offers significant concessions to drive volume will see ASP decline — but not for six months. During that interim period, reimbursement remains anchored to the earlier, higher ASP, creating a window in which margins are unusually generous. Conversely, a manufacturer that raises prices will see a delayed increase in ASP-based reimbursement, during which provider margins compress. The lag is symmetrical in theory but not in practice, because manufacturers have far more control over the timing of price changes than providers have over their purchasing decisions.
Commercial payers have adopted ASP as a reimbursement base for physician-administered drugs as well, though with varying markups. Some pay ASP plus ten or fifteen percent. Others negotiate flat fees. The result is a market in which the same drug, administered to different patients in the same clinic on the same day, generates different margins depending on the payer. The physician’s acquisition cost is constant. The reimbursement landscape is not.
What ASP measures accurately — the average net transaction price across all purchasers — is itself a construction worth scrutinizing. Because ASP includes Medicaid rebates and 340B chargebacks in its calculation, these deeply discounted transactions pull the average downward. A manufacturer selling a drug at WAC to commercial purchasers and at steep discounts to Medicaid and 340B entities will report an ASP that understates the commercial transaction price and overstates the government transaction price. The average is real. The individual transactions it averages are invisible.
This opacity matters for the expanding universe of stakeholders who rely on ASP data. Health economists modeling the cost-effectiveness of competing therapies. Investors estimating the revenue impact of biosimilar entry. Policy analysts evaluating whether ASP-based reimbursement achieves its stated objectives. Each user encounters the same limitation: ASP tells you what the market paid on average, two quarters ago, without revealing the distribution, the channel mix, or the concessions that produced the number. It is the best available approximation of a truth that no single metric can capture.
The six percent that seemed like a reasonable administrative markup when it was introduced has become something more: a load-bearing element in the economics of specialty medicine. Removing it, reducing it, or replacing it with a flat fee — all of which have been proposed — would redistribute revenue across providers, manufacturers, and payers in ways that are easier to model than to predict. The formula is simple. Its consequences are not.
